Monopar Therapeutics Files 2024 10-K

TL;DR

Monopar Therapeutics 2024 10-K filed: $14.3M assets, $6.1M cash, stock options detailed.

AI Summary

Monopar Therapeutics filed its 2024 10-K, reporting total assets of $14,338,403 as of December 31, 2024. The company had cash and cash equivalents of $6,102,560. The filing also details outstanding stock options, with 43,523 options vesting over time, and exercise prices ranging from $1.70 to $3.71 per share.

Why It Matters

This 10-K filing provides a comprehensive overview of Monopar Therapeutics' financial health and operational status as of the end of fiscal year 2024, crucial for investors assessing the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Monopar Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.

Key Numbers

• $14.3B — Total Assets (As of December 31, 2024, indicating the company's overall financial resources.)
• $6.1B — Cash and Cash Equivalents (As of December 31, 2024, representing readily available funds for operations.)
• 43,523 — Stock Options Vesting (Details on employee stock options that are scheduled to vest, impacting potential dilution.)

Key Players & Entities

• Monopar Therapeutics (company) — Filer of the 10-K
• December 31, 2024 (date) — Reporting period end date
• $14,338,403 (dollar_amount) — Total assets as of December 31, 2024
• $6,102,560 (dollar_amount) — Cash and cash equivalents as of December 31, 2024
• 43,523 (number) — Number of stock options vesting
• $1.70 (dollar_amount) — Lowest exercise price for stock options
• $3.71 (dollar_amount) — Highest exercise price for stock options

FAQ

From the Filing

0001437749-25-009979.txt : 20250331 0001437749-25-009979.hdr.sgml : 20250331 20250331080045 ACCESSION NUMBER: 0001437749-25-009979 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 74 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250331 DATE AS OF CHANGE: 20250331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 25788986 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 10-K 1 mnpr20241231_10k.htm FORM 10-K mnpr20241231_10k.htm 0001645469 Monopar Therapeutics Inc. false --12-31 FY 2024 true false true true false false false false false false 0.001 0.001 40,000,000 40,000,000 6,102,560 6,102,560 2,980,900 2,980,900 98,230 107,806 1,489,702 2,621,880 14,338,403 0 6,102,560 0.00 25.00 25.01 50.00 50.01 75.00 75.01 100.00 800 Forfeited options represent unvested shares and vested, expired shares related to employee terminations. Cash equivalents as of December 31, 2024 and 2023, represent the fair value of the Company’s investment in money market accounts and U.S. Treasury securities with maturities at the date of purchase of three months or less. 43,523 options vest as follows: options to purchase 41,523 shares of the Company’s common stock vest 6/48ths on the six-month anniversary of vesting commencement date and 1/48th per month thereafter; and options to purchase 2,000 shares of the Company’s common stock vest monthly over one year. Exercise prices range from $1.70 to $3.71 per share. Information pertaining to number of shares outstanding and per share data gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024. Forfeitures only include known forfeitures to-date as the Company typically accounts for forfeitures as they occur due to a limited history of forfeitures. Total provision for income taxes of $800 for each of the years ended December 31, 2024 and 2023, is recorded in general and administrative expenses on the Company’s consolidated statements of operations and comprehensive loss as it is not considered a material amount. 0001645469 2024-01-01 2024-12-31 iso4217:USD 0001645469 2024-06-30 xbrli:shares 0001645469 2025-03-14 thunderdome:item 0001645469 2024-10-01 2024-12-31 0001645469 2024-12-31 0001645469 2023-12-31 iso4217:USD xbrli:shares 0001645469 2023-01-01 2023-12-31 0001645469 us-gaap:CommonStockMember 2022-12-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001645469 us-gaap:RetainedEarningsMember 2022-12-31 0001645469 2022-12-31 0001645469 mnpr:CapitalOnDemandTMSalesAgreementMember 2023-01-01 2023-12-31 0001645469 us-gaap:CommonStockMember mnpr:CapitalOnDemandTMSalesAgreementMember 2023-01-01 2023-12-31 0001645469 us-gaap:AdditionalPaidInCapitalMember mnpr:CapitalOnDemandTMSalesAgreementMember 2023-01-01 2023-12-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember mnpr:CapitalOnDemandTMSalesAgreementMember 2023-01-01 2023-12-31 0001645469 us-gaap:RetainedEarningsMember mnpr:CapitalOnDemandTMSalesAgreementMember 2023-01-01 2023-12-31 0001645469 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001645469 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001645469 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001645469 us-gaap:ShareBasedPaymentArrangementNonemployeeMember us-gaap:RetainedE